Morgan Stanley maintains IDEXX Laboratories at Overweight, raises price target to $810 from $805

Morgan Stanley kept its Overweight rating on IDEXX Laboratories and increased its price target to $810 from $805. This suggests a 20.6% upside from the Nov 2 closing price of $671.64. Other recent analyst targets for IDEXX range from $700 to $750.

Original reporting
Published Nov 3, 2026, 5:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 5:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains IDEXX Laboratories at Overweight, raises price target to $810 from $805 — source image
Decision brief

The 30-second read

$IDXXBullishLow
01

Why it matters

For traders, the actionable element is the incremental valuation signal from the PT raise, not any new operational disclosure by IDEXX.

02

Market read

A modest price-target increase can support near-term sentiment, but the lack of new company-specific fundamentals keeps trading impact limited.

03

What to watch

Traders may already have priced in prior target ranges ($700 to $750) from recent notes, reducing incremental impact from a $5 PT step.

Relevance 4/10Novelty 4/10Timing: as of the analyst note publication date, for positioning around valuation sentiment

Background

The article summarizes a Morgan Stanley analyst action on IDEXX Laboratories, including a maintained rating and a slightly higher price target.

Company-level read

Ticker impact

$IDXXBullishMedium confidence
Context

Morgan Stanley maintained IDEXX Laboratories at Overweight and raised its price target to $810 from $805, signaling a modest valuation uplift.

Expected impact

Likely mild upward bias as traders price in the higher target, with limited follow-through absent new operational or earnings catalysts.

Evidence & confidence

This is an analyst note update (PT change) rather than a fresh earnings, guidance, or corporate event; the magnitude of the PT change is small and the article lacks a new thesis or data point.

Market effects

Limited read-through to the broader healthcare tools/diagnostics space because the update is a single-bank target change without new sector data.

Minimal, as the catalyst is company-specific analyst commentary.

Low, since the news is not tied to global macro, regulation, or cross-border operational developments.

Counterpoint

The PT increase may not matter if it is not accompanied by new earnings revisions or a stronger fundamental thesis; price action could fade quickly.

Key entities

  • IDEXX Laboratories

    Subject of the analyst action, rated Overweight with a raised price target to $810.

  • Morgan Stanley

    Issued the maintained rating and price target increase referenced in the article.

Related articles

$IDXXHighAI 8/10

IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook

IDEXX Laboratories reported Q3 2026 earnings, raising its full-year organic growth outlook to nearly 10% despite challenges. US clinic visits declined 1.8%, and macro pressures impacted puppy/kitten adoptions. CoVet acquisition is expected to dilute EPS by $0.13 in 2026. Global Rapid Assay revenues grew 1% organically. The company attributed growth to innovations, record instrument placements, and higher-quality visits.